File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Endothelium-dependent effects of carteolol

TitleEndothelium-dependent effects of carteolol
Authors
Issue Date1988
PublisherAmerican Society for Pharmacology and Experimental Therapeutics. The Journal's web site is located at http://jpet.aspetjournals.org
Citation
Journal Of Pharmacology And Experimental Therapeutics, 1988, v. 247 n. 2, p. 590-595 How to Cite?
AbstractExperiments were designed to study the effect of the beta adrenergic antagonist, carteolol, on the endothelium-dependent responsiveness of isolated arteries. Rings of canine coronary arteries were suspended in organ chambers for isometric tension recording; carteolol inhibited the relaxation to isoproterenol and abolished the difference in responsiveness to the beta adrenergic agonist between rings with and without endothelium. Carteolol did not cause endothelium-dependent relaxations of femoral or coronary arteries. In bioassay experiments, carteolol augmented the basal release of relaxing factors from the endothelium of the femoral artery; this effect was prevented by indomethacin. In rings of femoral arteries, carteolol increased the endothelium-dependent relaxations induced by the alpha-2 adrenergic agonist UK 14,304; this was not affected by indomethacin but prevented by propranolol. Carteolol did not modify the endothelium-dependent relaxations to acetylcholine, adenosine diphosphate, bradykinin, thrombin and the Ca+-ionophore A23187. Carteolol inhibited the endothelium-dependent hypoxic contraction of the canine coronary artery. It did not affect endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. These experiments suggest that carteolol facilitates the abluminal release of endothelium-dependent relaxing factor caused by alpha-2 adrenergic activation, and causes the intraluminal release of vasodilator prostaglandins. The compound prevents the endothelium-dependent contractions which are not mediated by products of cyclooxygenase. These actions may contribute to the vasodilator properties of carteolol in the intact organism.
Persistent Identifierhttp://hdl.handle.net/10722/170876
ISSN
2023 Impact Factor: 3.1
2023 SCImago Journal Rankings: 0.829
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorJanczewski, Pen_US
dc.contributor.authorBoulanger, Cen_US
dc.contributor.authorIqbal, Aen_US
dc.contributor.authorVanhoutte, PMen_US
dc.date.accessioned2012-10-30T06:11:14Z-
dc.date.available2012-10-30T06:11:14Z-
dc.date.issued1988en_US
dc.identifier.citationJournal Of Pharmacology And Experimental Therapeutics, 1988, v. 247 n. 2, p. 590-595en_US
dc.identifier.issn0022-3565en_US
dc.identifier.urihttp://hdl.handle.net/10722/170876-
dc.description.abstractExperiments were designed to study the effect of the beta adrenergic antagonist, carteolol, on the endothelium-dependent responsiveness of isolated arteries. Rings of canine coronary arteries were suspended in organ chambers for isometric tension recording; carteolol inhibited the relaxation to isoproterenol and abolished the difference in responsiveness to the beta adrenergic agonist between rings with and without endothelium. Carteolol did not cause endothelium-dependent relaxations of femoral or coronary arteries. In bioassay experiments, carteolol augmented the basal release of relaxing factors from the endothelium of the femoral artery; this effect was prevented by indomethacin. In rings of femoral arteries, carteolol increased the endothelium-dependent relaxations induced by the alpha-2 adrenergic agonist UK 14,304; this was not affected by indomethacin but prevented by propranolol. Carteolol did not modify the endothelium-dependent relaxations to acetylcholine, adenosine diphosphate, bradykinin, thrombin and the Ca+-ionophore A23187. Carteolol inhibited the endothelium-dependent hypoxic contraction of the canine coronary artery. It did not affect endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. These experiments suggest that carteolol facilitates the abluminal release of endothelium-dependent relaxing factor caused by alpha-2 adrenergic activation, and causes the intraluminal release of vasodilator prostaglandins. The compound prevents the endothelium-dependent contractions which are not mediated by products of cyclooxygenase. These actions may contribute to the vasodilator properties of carteolol in the intact organism.en_US
dc.languageengen_US
dc.publisherAmerican Society for Pharmacology and Experimental Therapeutics. The Journal's web site is located at http://jpet.aspetjournals.orgen_US
dc.relation.ispartofJournal of Pharmacology and Experimental Therapeuticsen_US
dc.subject.meshAcetylcholine - Pharmacologyen_US
dc.subject.meshAdrenergic Beta-Antagonists - Pharmacologyen_US
dc.subject.meshAnimalsen_US
dc.subject.meshBiological Assayen_US
dc.subject.meshCarteolol - Pharmacologyen_US
dc.subject.meshDogsen_US
dc.subject.meshEndothelium, Vascular - Drug Effectsen_US
dc.subject.meshFemaleen_US
dc.subject.meshIsoproterenol - Pharmacologyen_US
dc.subject.meshMaleen_US
dc.subject.meshPropanolamines - Pharmacologyen_US
dc.subject.meshRatsen_US
dc.subject.meshRats, Inbred Shren_US
dc.subject.meshRats, Inbred Strainsen_US
dc.subject.meshReceptors, Adrenergic, Alpha - Metabolismen_US
dc.subject.meshVasodilation - Drug Effectsen_US
dc.titleEndothelium-dependent effects of carteololen_US
dc.typeArticleen_US
dc.identifier.emailVanhoutte, PM:vanhoutt@hku.hken_US
dc.identifier.authorityVanhoutte, PM=rp00238en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid2903235-
dc.identifier.scopuseid_2-s2.0-0023756438en_US
dc.identifier.volume247en_US
dc.identifier.issue2en_US
dc.identifier.spage590en_US
dc.identifier.epage595en_US
dc.identifier.isiWOS:A1988Q971200028-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridJanczewski, P=6507997193en_US
dc.identifier.scopusauthoridBoulanger, C=7006599024en_US
dc.identifier.scopusauthoridIqbal, A=7005402770en_US
dc.identifier.scopusauthoridVanhoutte, PM=7202304247en_US
dc.identifier.issnl0022-3565-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats